Johnson & Johnson delivered a quarter that looks different depending on which bar you use. Adjusted EPS of $2.59 cleared the $2.53 consensus but fell well short of the $2.93 Earnings Whisper, an 11.6% miss against the number investors were actually positioned for. Adjusted earnings fell 7.5% year over year even as revenue rose 5.9% to $25.4 billion, which was 0.2% shy of consensus. That is the central tension. The top line is improving, led by a pharma franchise that keeps outrunning the Stelara cliff, but deal spending, margin compression and a faltering MedTech business are absorbing the growth before it reaches the bottom line.

The quality of the quarter deserves scrutiny on both the GAAP and adjusted lines. GAAP EPS collapsed to $0.09 from $2.12, driven mainly by a $5.5 billion pre-tax litigation charge tied to the proposed ovarian talc resolution. The adjusted figure also absorbed costs. Management said it reflects the Firefly Bio acquisition and the Sail Biomedicines collaboration, and research and development expense jumped 26.7% to 18.3% of sales from 15.3%. Gross margin slipped to 68.1% from 69.6%, and adjusted pre-tax margin fell to 30.2% from 35.2%. Innovative Medicine's adjusted pre-tax margin dropped to roughly 35% from 44%. A lower adjusted tax rate of 17.4% versus 19.4% cushioned the decline. Earnings momentum is clearly decelerating. Nine-month adjusted EPS is down only 1.7%, so the third quarter marked a sharp step down.

Beneath the margin pressure, the operating story in pharma strengthened. Operational sales growth accelerated to 6.0% from 5.6% in the second quarter. Innovative Medicine improved to 7.9% from 6.8% despite roughly 690 basis points of drag from Stelara, whose sales fell 54%. Oncology grew about 17% on an operational basis, with these contributions:

- Darzalex reached $4.2 billion in sales.

- Carvykti rose 35%.

- Tecvayli rose 77%.

- Rybrevant/Lazcluze rose 64%.

Tremfya climbed 68% to $2.4 billion. Caplyta grew 66% and has passed $1 billion year to date. Icotide roughly doubled its patient base from the second quarter to more than 20,000. Patent erosion remains visible elsewhere, with Opsumit down 35%, Imbruvica down 18% and Simponi down 17%. Still, the new-product engine is clearly out-running the losses.

MedTech is where bears have legitimate ammunition. Segment growth slowed to 2.5%, down from 3.6% in the second quarter, 4.6% in the first quarter and 5.8% in the fourth quarter of 2025. International MedTech sales were essentially flat at 0.1%. Surgery declined about 1%, and Abiomed fell for a second straight quarter. Electrophysiology growth cooled to 4.4% from 9.5% in the first quarter amid intensifying pulsed field ablation competition in Asia-Pacific. Management acknowledged that results fell below communicated expectations and flagged Middle East disruption to tenders and hospital ordering as a new headwind. Shockwave, up 17%, and trauma were bright spots. The FDA authorization of the OTTAVA robotic system, with a first commercial customer signed, gives the segment a longer-term catalyst. The leaning toward a DePuy Synthes spin by mid-2027 adds a structural one.

Guidance requires careful reading because the comparisons conflict:

- **Reported sales:** The midpoint edged up to $101.2 billion, or 7.4% growth.

- **Operational growth:** The range tightened to 6.7%-7.1%.

- **Adjusted EPS versus the late-July outlook:** The release presents a $0.06 raise to an $11.10 midpoint, measured against the deal-adjusted outlook issued July 29.

- **Adjusted EPS versus the original second-quarter outlook:** The call analysis shows guidance reset from $11.68 because of $0.64 of Firefly/Sail in-process R&D.

- **Operating margin:** The full-year outlook now implies about a 60 basis-point decline, compared with an improvement before the deals.

- **Supporting items:** Interest expense guidance was lowered, and free cash flow of roughly $21 billion was reaffirmed.

The bigger forward issue is that management sees $1.36 of deal dilution in 2027 plus an FX headwind from the stronger dollar, even as it reiterated double-digit growth by decade's end and said 2027 will be better. The talc resolution also remains contingent on 95% claimant participation, which management described as trending toward the threshold.

Investors came into the print constructive but cooling. Earnings Whispers sentiment remained positive but weakened modestly, slipping to 0.22 from 0.29. Shares were up 5.5% since the opening after the July report and 8.5% above the 200-day moving average. They sat 6.2% below the $281.07 52-week high set on September 2 and 7.4% above the inter-earnings low. In other words, the stock had already given back part of its late-summer run before the report. Supporting trend readings for sequential growth, momentum and AVWAP remain positive, while price trend is neutral.

The bottom line is that J&J's pharma growth story got better this quarter, but almost nothing else did. The consensus beat is real. However, the miss against the whisper, a 7.5% earnings decline, compressing margins, a decelerating MedTech segment and heavier 2027 dilution make the setup more complicated than the headline implies. Growth-oriented holders can point to accelerating Innovative Medicine sales and a credible pipeline. Skeptics can point to earnings that are moving the wrong way while the company spends to build that future.